As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Treatment Study for Patients with Localized Central Nervous System Germ Cell Tumors
To determine, as measured by the 3-year progression free survival rate and patterns of failure, whether simplified chemotherapy followed by dose-reduced radiation therapy is effective for treating children and young adults (ages 3 to < 21 years) with localized primary central nervous system (CNS) germinoma who present with serum and/or CSF human chorionic gonadotropin-beta (hCGI3) < 50miU/ml.
In order to participate you must meet the following criteria:
- Are between 3 and 21 years of age at the time of study enrollment.
- Have been newly diagnosed with localized primary CNS NGGCT (Stratum 1) or localized primary CNS germinoma (Stratum 2). Germ cell tumors located in the suprasellar pineal, bifocal (pineal + suprasellar) and ventricles are eligible. Tumors present in the above mentioned locations and with unifocal parenchymal extension are eligible.
This is a partial list of elgibility requirements.